( ditionalinformation please visit

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of the final results of the RAPID clinical study of pixantrone to have the same or similar results to the interim analysis, or the potential failure of pixantrone to prove safe and effective for treatment of non-Hodgkin's lymphoma or other cancers, determinations by regulatory, patent and administrative governmental authorities, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's most recent filings on Forms 10- K, 8-K, and 10-Q. Except as may be required by Italian law, CTI is under no obligation to (and expressly disclaims any such obligation to) update or alter

its forward-looking statements whether as a result of new information, future

events, or otherwise.


    Media Contact:

    Dan Eramian

    T: 206.272.4343

    C: 206.854.1200


    Susan Callahan

    T: 206.272.4472

    F: 206.272.4434

    E: 

    http://www.cticseattle.com/media.htm


    Investors Contact:

    Leah Grant

    T: 206.282.7100

    F: 206.272.4434

    E: 

    http://www.cticseattle.com/investors.htm


    Medic
'"/>




Page: 1 2 3 4 5 
Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement
of Interim Pixantrone Study Results
2. Publication on Pixantrone Preclinical Studies Demonstrates Reduced
Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and
Mitoxantrone
3. Pixantrone Granted Fast Track Designation by FDA for Relapsed
Indolent NHL Patients
4. New Phase 3 Study Published in The Lancet Evaluates Efficacy and
Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination
Therapy in Treatment-Experienced Adults With HIV
5. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib
Combination Studies
6. An Investigational Study Released at ADA Showed that Initial
Combination Therapy with Januvia (sitagliptin) and Metformin Led to
Improvement in Markers of Beta Cell Function in Patients with Type
2 Diabetes
7. Late Breaking Data Released at ADA Showed that the Investigational
Use of Januvia and Metformin as Initial Combination Therapy
Provided Significant Glucose Lowering Efficacy over 54 Weeks in
Patients with Type 2 Diabetes
8. Poniard Pharmaceuticals Announces Promising Data From Interim
Safety Analysis of Phase 1 Combination Trials of Picoplatin in
Colorectal and Prostate Cancers
9. Peregrine Pharmaceuticals Reports Positive Top-Line Results in
Bavituximab Combination Therapy Trial in Advanced Cancer Patients
10. Intarcia Therapeutics Announces Presentation of Final Results From
a Phase 2 Combination Study for the Treatment of Hepatitis C at the
Digestive Disease Week Conference
11. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure
as Long-Term Monotherapy and in Combination Therapy